Altmetric

Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin

File Description SizeFormat 
Reglinski_and_Sriskandan_supplementary_methods.pdfSupporting information36.52 kBAdobe PDFView/Open
Reglinski_Treatment potential of pathogen_BMC.pdfPublished version1.36 MBAdobe PDFView/Open
Title: Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin
Authors: Reglinski, M
Sriskandan, S
Item Type: Journal Article
Abstract: Objective Intravenous immune globulin (IVIG), pooled from human blood, is a polyspecific antibody preparation that inhibits the super-antigenic proteins associated with streptococcal and staphylococcal toxic shock, and the Shiga toxin. In addition to this toxin-neutralising activity, IVIG contains other pathogen-reactive antibodies that may confer additional therapeutic benefits. We sought to determine if pathogen-reactive antibodies that promote opsonophagocytosis of different organisms can be sequentially affinity-purified from one IVIG preparation. Results Antibodies that recognise cell wall antigens of Streptococcus pyogenes, Staphylococcus aureus, and vancomycin-resistant enterococcus (VRE) were sequentially affinity-purified from a single preparation of commercial IVIG and opsonophagocytic activity was assessed using a flow cytometry assay of neutrophil uptake. Non-specific IgG-binding proteins were removed from the S. aureus preparations using an immobilised Fc fragment column, produced using IVIG cleaved with the Immunoglobulin G-degrading enzyme of S. pyogenes (IdeS). Affinity-purified anti-S. aureus and anti-VRE immunoglobulin promoted significantly higher levels of opsonophagocytic uptake by human neutrophils than IVIG when identical total antibody concentrations were compared, confirming activity previously shown for affinity-purified anti-S. pyogenes immunoglobulin. The opsonophagocytic activities of anti-S. pyogenes, anti-S. aureus, and anti-VRE antibodies that were sequentially purified from a single IVIG preparation were undiminished compared to antibodies purified from previously unused IVIG.
Issue Date: 15-Apr-2019
Date of Acceptance: 4-Apr-2019
URI: http://hdl.handle.net/10044/1/70079
DOI: https://dx.doi.org/10.1186/s13104-019-4262-8
ISSN: 1756-0500
Publisher: BioMed Central
Journal / Book Title: BMC Research Notes
Volume: 12
Copyright Statement: © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated
Sponsor/Funder: Medical Research Council (MRC)
Medical Research Council (MRC)
Medical Research Council (MRC)
National Institute for Health Research
National Institute for Health Research
Wellcome Trust
Funder's Grant Number: G0800777
G0800777
MC_PC_12015
HPRU-2012-10047
HPRU-2012-10047
087732/Z/08/Z
Keywords: Antimicrobial resistance
Enterococcus
IVIG
Opsonophagocytic killing
Pooled human immunoglobulin
Staphylococcus aureus
1199 Other Medical and Health Sciences
Bioinformatics
Publication Status: Published
Article Number: ARTN 228
Appears in Collections:Department of Medicine
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons